Jacob Chacko, ORIC Pharmaceuticals CEO
March 23, 2022 07:20 AM EDTUpdated 10:26 AM
R&D

An­oth­er small biotech watch­es its lead drug im­plode as its stock price tanks

John Carroll

Editor & Founder

Close to 2 years af­ter ORIC Phar­ma­ceu­ti­cals went pub­lic with an IPO boast­ing of the po­ten­tial of its lead can­cer drug, the biotech has joined …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

At least sev­en drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions 

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Paci­ra ab­sorbs GQ Bio for $32M; Lay­offs at BMS, Ei­sai and CRISPR Ther­a­peu­tics

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times